For research use only.
Ipamorelin
Ipamorelin is a lab-made pentapeptide that triggers growth hormone release through the ghrelin receptor, with a more selective GH signal than older GHRP peptides in animal tests.[1]
Research areas
Animal pharmacology and one human trial frame the research so far.
- Selective GH release in rats and swine, without the ACTH and cortisol rises seen with GHRP-6 and GHRP-2 in those models[1]
- Postoperative ileus after bowel surgery, in a phase 2 randomized trial that did not meet its key efficacy endpoint[2]
- GH release through a GHRP-like (ghrelin) receptor pathway, distinct from GHRH[1][3]
Evidence level
Level 3 of 4: Small human trialsA phase 2 randomized, placebo-controlled trial in 117 bowel-resection patients tested intravenous ipamorelin for postoperative ileus.[2]
Why so few human trials?Cautions
Studies and regulators point to several reasons for care.
- FDA notes a published study that identified serious adverse events, including death, when ipamorelin was given intravenously for gastric motility, and says it lacks enough safety information for certain other injectable routes[4]
- The phase 2 postoperative ileus trial did not show a significant benefit over placebo on its key efficacy endpoint[2]
Ipamorelin is not FDA approved.[4]
Ipamorelin goes by several names.
- Ghrelin-receptor agonist, or ghrelin mimetic[2]
- Growth hormone secretagogue[1]
- Ipamorelin acetate, its salt form[4]
Often stacked with
CJC-1295. CJC-1295 and ipamorelin are paired because they flip two different switches for GH release, so one doesn’t just repeat the other.[1][5]
Good to know
In swine tests, ipamorelin raised GH without significantly raising ACTH or cortisol, unlike GHRP-6 and GHRP-2 in the same models.[1]
Storage basics General
These general basics apply to most freeze-dried research peptides.
Sources and studies
These studies and official pages are the research behind this profile.
- 1Ipamorelin, the first selective growth hormone secretagogueRaun K, et al. (1998) · European Journal of Endocrinology
- 2Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsBeck DE, et al. (2014) · International Journal of Colorectal Disease
- 3Ghrelin is a growth-hormone-releasing acylated peptide from stomachKojima M, et al. (1999) · Nature
- 4Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration (2026)
- 5Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analogJetté L, et al. (2005) · Endocrinology
- 6Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormoneBowers CY, et al. (1990) · The Journal of Clinical Endocrinology & Metabolism